High-density Lipoprotein As a Potential Carrier for Delivery of a Lipophilic Antitumoral Drug into Hepatoma Cells

Overview

Journal World J Gastroenterol

Publisher Baishideng Publishing Group

Specialty Gastroenterology

Date 2005 Mar 3

PMID 15742395

Citations 21

Authors

Bin Lou

Xue-Ling Liao

Man-Ping Wu

Pei-Fang Cheng

Chun-Yan Yin

Zheng Fei

Affiliations

Soon will be listed here.

Abstract

Aim: To investigate the possibility of recombinant high-density lipoprotein (rHDL) being a carrier for delivering antitumoral drug to hepatoma cells.

Methods: Recombinant complex of HDL and aclacinomycin (rHDL-ACM) was prepared by cosonication of apoproteins from HDL (Apo HDL) and ACM as well as phosphatidylcholine. Characteristics of the rHDL-ACM were elucidated by electrophoretic mobility, including the size of particles, morphology and entrapment efficiency. Binding activity of rHDL-ACM to human hepatoma cells was determined by competition assay in the presence of excess native HDL. The cytotoxicity of rHDL-ACM was assessed by MTT method.

Results: The density range of rHDL-ACM was 1.063-1.210 g/mL, and the same as that of native HDL. The purity of all rHDL-ACM preparations was more than 92%. Encapsulated efficiencies of rHDL-ACM were more than 90%. rHDL-ACM particles were typical sphere model of lipoproteins and heterogeneous in particle size. The average diameter was 31.26+/-5.62 nm by measure of 110 rHDL-ACM particles in the range of diameter of lipoproteins. rHDL-ACM could bind on SMMC-7721 cells, and such binding could be competed against in the presence of excess native HDL. rHDL-ACM had same binding capacity as native HDL. The cellular uptake of rHDL-ACM by SMMC-7721 hepatoma cells was significantly higher than that of free ACM at the concentration range of 0.5-10 microg/mL (P<0.01). Cytotoxicity of rHDL-ACM to SMMC-7721 cells was significantly higher than that of free ACM at concentration range of less than 5 microg/mL (P<0.01) and IC50 of rHDL-ACM was lower than IC50 of free ACM (1.68 nmol/L vs 3 nmol/L). Compared to L02 hepatocytes, a normal liver cell line, the cellular uptake of rHDL-ACM by SMMC-7721 cells was significantly higher (P<0.01) and in a dose-dependent manner at the concentration range of 0.5-10 microg/mL. Cytotoxicity of the rHDL-ACM to SMMC-7721 cells was significantly higher than that to L02 cells at concentration range of 1-7.5 microg/mL (P<0.01). IC50 for SMMC-7721 cells (1.68 nmol/L) was lower than that for L02 cells (5.68 nmol/L), showing a preferential cytotoxicity of rHDL-ACM for SMMC-7721 cells.

Conclusion: rHDL-ACM complex keeps the basic physical and biological binding properties of native HDL and shows a preferential cytotoxicity for SMMC-7721 hepatoma to normal L02 hepatocytes. HDL is a potential carrier for delivering lipophilic antitumoral drug to hepatoma cells.

Citing Articles

HDL and Therapy.

Li K, Xie X, Guo Y Adv Exp Med Biol. 2022; 1377:171-187.

PMID: 35575930 DOI: 10.1007/978-981-19-1592-5_14.

Role of Lipids and Apolipoproteins in Predicting the Prognosis of Hepatocellular Carcinoma After Resection.

Ni X, Yi Y, Fu Y, Cai X, Liu G, Huang J Onco Targets Ther. 2020; 13:12867-12880.

PMID: 33376344 PMC: 7756018. DOI: 10.2147/OTT.S279997.

Synthetic HDL Nanoparticles Delivering Docetaxel and CpG for Chemoimmunotherapy of Colon Adenocarcinoma.

Scheetz L, Yu M, Li D, Castro M, Moon J, Schwendeman A Int J Mol Sci. 2020; 21(5).

PMID: 32150841 PMC: 7084365. DOI: 10.3390/ijms21051777.

Biomacromolecules as carriers in drug delivery and tissue engineering.

Zhang Y, Sun T, Jiang C Acta Pharm Sin B. 2018; 8(1):34-50.

PMID: 29872621 PMC: 5985630. DOI: 10.1016/j.apsb.2017.11.005.

Detecting the functional complexities between high-density lipoprotein mimetics.

Sei Y, Ahn J, Kim T, Shin E, Santiago-Lopez A, Jang S Biomaterials. 2018; 170:58-69.

PMID: 29653287 PMC: 5918464. DOI: 10.1016/j.biomaterials.2018.04.011.

References

Tokui T, Kuroiwa C, Muramatsu S, Tokui Y, Sasagawa K, Ikeda T . Plasma lipoproteins as targeting carriers to tumour tissues after administration of a lipophilic agent to mice. Biopharm Drug Dispos. 1995; 16(2):91-103. DOI: 10.1002/bdd.2510160204. View

Masquelier M, Tirzitis G, Peterson C, Palsson M, Amolins A, Plotniece M . Plasma stability and cytotoxicity of lipophilic daunorubicin derivatives incorporated into low density lipoproteins. Eur J Med Chem. 2000; 35(4):429-38. DOI: 10.1016/s0223-5234(00)00139-2. View

Lundberg B, Suominen L . Preparation of biologically active analogs of serum low density lipoprotein. J Lipid Res. 1984; 25(6):550-8. View

Rinninger F, Brundert M, Fruchart J, Greten H, Castro G . Scavenger receptor BI (SR-BI) mediates a higher selective cholesteryl ester uptake from LpA-I compared with LpA-I:A-II lipoprotein particles. Atherosclerosis. 2002; 166(1):31-40. DOI: 10.1016/s0021-9150(02)00311-8. View

Pussinen P, Lindner H, Glatter O, Reicher H, Kostner G, Wintersperger A . Lipoprotein-associated alpha-tocopheryl-succinate inhibits cell growth and induces apoptosis in human MCF-7 and HBL-100 breast cancer cells. Biochim Biophys Acta. 2000; 1485(2-3):129-44. DOI: 10.1016/s1388-1981(00)00035-4. View

Scanu A . Forms of human serum high density lipoprotein protein. J Lipid Res. 1966; 7(2):295-306. View

Schumaker V, Puppione D . Sequential flotation ultracentrifugation. Methods Enzymol. 1986; 128:155-70. DOI: 10.1016/0076-6879(86)28066-0. View

Rensen P, de Vrueh R, Kuiper J, Bijsterbosch M, Biessen E, Van Berkel T . Recombinant lipoproteins: lipoprotein-like lipid particles for drug targeting. Adv Drug Deliv Rev. 2001; 47(2-3):251-76. DOI: 10.1016/s0169-409x(01)00109-0. View

Bijsterbosch M, Schouten D, Van Berkel T . Synthesis of the dioleoyl derivative of iododeoxyuridine and its incorporation into reconstituted high density lipoprotein particles. Biochemistry. 1994; 33(47):14073-80. DOI: 10.1021/bi00251a016. View

10.

Pieters M, Schouten D, Van Berkel T . In vitro and in vivo evidence for the role of HDL in reverse cholesterol transport. Biochim Biophys Acta. 1994; 1225(2):125-34. DOI: 10.1016/0925-4439(94)90069-8. View

11.

de Smidt P, Van Berkel T . LDL-mediated drug targeting. Crit Rev Ther Drug Carrier Syst. 1990; 7(2):99-120. View

12.

Khazaeli M, Conry R, LoBuglio A . Human immune response to monoclonal antibodies. J Immunother Emphasis Tumor Immunol. 1994; 15(1):42-52. DOI: 10.1097/00002371-199401000-00006. View

13.

Hauser H, Kostner G . Structural organization of free and esterified cholesterol in human high density lipoproteins. A 100.6 MHz 13C NMR study. Biochim Biophys Acta. 1979; 573(2):375-81. DOI: 10.1016/0005-2760(79)90070-5. View

14.

Acton S, Rigotti A, Landschulz K, Xu S, Hobbs H, Krieger M . Identification of scavenger receptor SR-BI as a high density lipoprotein receptor. Science. 1996; 271(5248):518-20. DOI: 10.1126/science.271.5248.518. View

15.

Acton S, Kozarsky K, Rigotti A . The HDL receptor SR-BI: a new therapeutic target for atherosclerosis?. Mol Med Today. 1999; 5(12):518-24. DOI: 10.1016/s1357-4310(99)01600-7. View

16.

Favre G, Canal P, Soula G . Low density lipoprotein for cytotoxic drug targeting: improved activity of elliptinium derivative against B16 melanoma in mice. Br J Cancer. 1993; 68(2):319-26. PMC: 1968583. DOI: 10.1038/bjc.1993.335. View

17.

Lenz M, Miehe W, Vahrenwald F, Bruchelt G, Schweizer P, Girgert R . Cholesterol based antineoplastic strategies. Anticancer Res. 1997; 17(2A):1143-6. View

18.

Pittman R, Glass C, Atkinson D, Small D . Synthetic high density lipoprotein particles. Application to studies of the apoprotein specificity for selective uptake of cholesterol esters. J Biol Chem. 1987; 262(6):2435-42. View

19.

Kader A, Davis P, Kara M, Liu H . Drug targeting using low density lipoprotein (LDL): physicochemical factors affecting drug loading into LDL particles. J Control Release. 1998; 55(2-3):231-43. DOI: 10.1016/s0168-3659(98)00052-2. View

20.

Kader A, Pater A . Loading anticancer drugs into HDL as well as LDL has little affect on properties of complexes and enhances cytotoxicity to human carcinoma cells. J Control Release. 2002; 80(1-3):29-44. DOI: 10.1016/s0168-3659(01)00536-3. View